Payment overview · 2025
General Payments
$424.36
17 reported records · 11 companies
Healthcare provider profile · identity verified
Bruce A Blacker, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CHICAGO, IL · NPI 1982603924
Verified facts
What the public records show
CMS Open Payments records show Bruce A Blacker, M.D. received $424.36 in general payments during 2025 across 17 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 17.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Biktarvy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $72.30 | 17.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $69.40 | 16.4% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $61.41 | 14.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.64 | 10.3% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $33.28 | 7.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.40 | 6.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.06 | 6.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.35 | 6.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.17 | 5.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.57 | 4.8% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.78 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $424.36 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $92.87 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $61.41 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $45.93 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.40 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.01 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.01 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $28.06 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 178 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 14 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
178 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 563 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 377 | 76 |
| Lisinopril | Lisinopril | 282 | 45 |
| Metformin Hcl | Metformin Hcl | 237 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 226 | 48 |
| Losartan Potassium | Losartan Potassium | 221 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 195 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 193 | 30 |
| Eliquis | Apixaban | 178 | 35 |
| Furosemide | Furosemide | 176 | 47 |
| Gabapentin | Gabapentin | 153 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 35 |
| Mirtazapine | Mirtazapine | 105 | 14 |
| Simvastatin | Simvastatin | 104 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 103 | 15 |
| Trazodone Hcl | Trazodone Hcl | 101 | 21 |
| Carvedilol | Carvedilol | 99 | 20 |
| Levetiracetam | Levetiracetam | 96 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 16 |
| Jardiance | Empagliflozin | 73 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 73 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 25 |
| Tramadol Hcl | Tramadol Hcl | 69 | 13 |
| Lorazepam | Lorazepam | 65 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 22 |
| Spironolactone | Spironolactone | 64 | 25 |
| Allopurinol | Allopurinol | 62 | 14 |
| Glipizide | Glipizide | 62 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 29 |
| Sertraline Hcl | Sertraline Hcl | 57 | suppressed |
| Alprazolam | Alprazolam | 54 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | suppressed |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 13 |
| Hydromorphone Hcl | Hydromorphone Hcl | 48 | suppressed |
| Omeprazole | Omeprazole | 48 | 12 |
| Pregabalin | Pregabalin | 48 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 16 |
| Famotidine | Famotidine | 46 | 12 |
| Montelukast Sodium | Montelukast Sodium | 45 | 11 |
| Digoxin | Digoxin | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 39 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Potassium Chloride | Potassium Chloride | 38 | 19 |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | 11 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 18 |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 15 |
| Ozempic | Semaglutide | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Prednisone | Prednisone | 19 | 13 |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 13 |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 16 | suppressed |
| Mytesi | Crofelemer | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Valsartan | Valsartan | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 11 | 11 |
| Bumetanide | Bumetanide | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $424.36 · 17 records | Otsuka America Pharmaceutical, Inc. | AUSTEDO XR, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, KRYSTEXXA, LEQVIO, NURTEC ODT, PAXLOVID, REXULTI, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error